An oral TRPV1 antagonist attenuates laser radiant-heat-evoked potentials and pain ratings from UV(B) -inflamed and normal skin.

Trial Profile

An oral TRPV1 antagonist attenuates laser radiant-heat-evoked potentials and pain ratings from UV(B) -inflamed and normal skin.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jul 2012

At a glance

  • Drugs ABT 102; Etoricoxib; Tramadol
  • Indications Pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Nov 2010 New trial record.
    • 13 Sep 2010 Primary endpoint 'Pain-measures' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top